All of Lupin Diagnostics Limited’s (LDL) greenfield labs have received 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation. LDL is a fully owned subsidiary of the multinational pharmaceutical giant Lupin Limited (Lupin).

“The team’s commitment to patient care and our goal of encouraging healthier lives are demonstrated by this accreditation. The nation’s 27 greenfield labs guarantee accurate and timely reporting. With evidence-based diagnostics, we want to empower physicians and patients. We are still dedicated to improving healthcare via innovation and ongoing improvement,” said Ravindra Kumar, CEO of Lupin Diagnostics.

This noteworthy accomplishment demonstrates the strict adherence to quality control procedures, reaffirming LDL’s unwavering commitment to offering superior diagnostic services. Every facet of the business’s operations demonstrates its dedication to quality, guaranteeing that patients receive reliable, timely, and accurate results.

The recent achievements of Lupin Diagnostics include receiving the prestigious titles of ‘Patient-Centric Diagnostic Laboratories Company of the Year’ at the IHW 3rd Patients First Award 2024, ‘Emerging Diagnostics Chain of the Year’ at the Diagnostics Innovation and Excellence Award 2024 by Voice of Healthcare, and ‘Pathology Lab of the Year’ (National Category) at the ET Healthcare Awards in 2022 and 2024. These accolades highlight the business’s commitment to patient-centered care and its dominant position in the diagnostics sector.

For more details, visit: https://www.lupindiagnostics.com/

Priyanka Dutta